KR20200043534A - 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 - Google Patents

알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 Download PDF

Info

Publication number
KR20200043534A
KR20200043534A KR1020207011211A KR20207011211A KR20200043534A KR 20200043534 A KR20200043534 A KR 20200043534A KR 1020207011211 A KR1020207011211 A KR 1020207011211A KR 20207011211 A KR20207011211 A KR 20207011211A KR 20200043534 A KR20200043534 A KR 20200043534A
Authority
KR
South Korea
Prior art keywords
alkyl
phenyl
autism
glyx
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207011211A
Other languages
English (en)
Korean (ko)
Inventor
요셉 모스칼
Original Assignee
노오쓰웨스턴 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노오쓰웨스턴 유니버시티 filed Critical 노오쓰웨스턴 유니버시티
Publication of KR20200043534A publication Critical patent/KR20200043534A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207011211A 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 Ceased KR20200043534A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161479593P 2011-04-27 2011-04-27
US61/479,593 2011-04-27
US201161527744P 2011-08-26 2011-08-26
US61/527,744 2011-08-26
PCT/US2012/035547 WO2012149389A2 (en) 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008907A Division KR20190037359A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011613A Division KR20210046843A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Publications (1)

Publication Number Publication Date
KR20200043534A true KR20200043534A (ko) 2020-04-27

Family

ID=47073094

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020207011211A Ceased KR20200043534A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020137031028A Ceased KR20140043078A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020217011613A Ceased KR20210046843A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020197008907A Ceased KR20190037359A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020187022910A Ceased KR20180095096A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020137031028A Ceased KR20140043078A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020217011613A Ceased KR20210046843A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020197008907A Ceased KR20190037359A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020187022910A Ceased KR20180095096A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Country Status (13)

Country Link
US (4) US20140107037A1 (enExample)
EP (2) EP2701721A4 (enExample)
JP (1) JP6035326B2 (enExample)
KR (5) KR20200043534A (enExample)
CN (2) CN103974712A (enExample)
AU (1) AU2012249397B2 (enExample)
BR (1) BR112013027554A2 (enExample)
CA (1) CA2834286A1 (enExample)
EA (2) EA029999B1 (enExample)
HK (1) HK1258231A1 (enExample)
MX (1) MX357761B (enExample)
SG (2) SG10202010665YA (enExample)
WO (1) WO2012149389A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220029192A (ko) 2020-09-01 2022-03-08 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
WO2011100585A1 (en) 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
PE20151416A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
JP2016506962A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
US9758525B2 (en) 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9745342B2 (en) * 2013-10-28 2017-08-29 Naurex, Inc. NMDA receptor modulators and prodrugs, salts, and uses thereof
CN111920412A (zh) * 2013-12-13 2020-11-13 西北大学 治疗脑部病症或鉴定与其相关的生物标记的方法
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
AU2015280108B2 (en) * 2014-06-23 2019-11-28 Naurex, Inc. Methods of treating or ameliorating migraine
CN108601814A (zh) * 2015-10-16 2018-09-28 西北大学 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
KR102465758B1 (ko) 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
WO2009105718A1 (en) * 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220029192A (ko) 2020-09-01 2022-03-08 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2012149389A3 (en) 2014-05-08
US20190209642A1 (en) 2019-07-11
EA029999B1 (ru) 2018-06-29
HK1258231A1 (zh) 2019-11-08
KR20190037359A (ko) 2019-04-05
KR20140043078A (ko) 2014-04-08
EA201391581A1 (ru) 2014-05-30
AU2012249397B2 (en) 2017-03-30
SG10202010665YA (en) 2020-11-27
EP2701721A4 (en) 2015-12-16
CN108283712A (zh) 2018-07-17
KR20210046843A (ko) 2021-04-28
JP2014520072A (ja) 2014-08-21
EP3679931A3 (en) 2020-10-14
US20140107037A1 (en) 2014-04-17
KR20180095096A (ko) 2018-08-24
WO2012149389A2 (en) 2012-11-01
US20210169964A1 (en) 2021-06-10
SG194230A1 (en) 2013-12-30
CA2834286A1 (en) 2012-11-01
JP6035326B2 (ja) 2016-11-30
EA201790653A1 (ru) 2017-07-31
US20170049845A1 (en) 2017-02-23
MX357761B (es) 2018-07-23
MX2013012526A (es) 2014-04-16
CN103974712A (zh) 2014-08-06
EP3679931A2 (en) 2020-07-15
BR112013027554A2 (pt) 2016-09-06
AU2012249397A1 (en) 2013-11-07
EP2701721A2 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
KR20200043534A (ko) 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
Chen et al. Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: converging insights from alternative hypotheses
Stettner et al. Breathing dysfunctions associated with impaired control of postinspiratory activity in Mecp2−/y knockout mice
Hajos et al. Targeting α7 nicotinic acetylcholine receptors in the treatment of schizophrenia
Hunsley et al. Altered sleep latency and arousal regulation in mice lacking norepinephrine
White et al. Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models
Shudo et al. A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm
Zhu et al. CX3CL1 attenuates neurological deficit and neuroinflammation through CX3CR1/p38 MAPK/ERK1/2 signaling pathway in traumatic brain injury
Mir et al. Proton pump inhibitor “Lansoprazole” inhibits locus coeruleus’s neuronal activity and increases rapid eye movement sleep
RS66337B1 (sr) Režimi doza za upotrebu ly3154207 u lečenju dopaminergičkih poremećaja cns-a
US6942979B1 (en) Method for screening substances capable of modulating the activity of a TRAAK potassium channel
WO2012170452A2 (en) Compositions and methods for treating neurodegenerative diseases
Razumovskaya et al. Modulation of nicotinic receptors in neurons in the common snail by Noopept and Piracetam
HK40034037A (en) Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
JPH10508579A (ja) シナプス伝達を改善する薬
Yang et al. TREK-1 and epilepsy: regulating the balance of K+ and the glutamate release in astrocyte-neuron interactions
He et al. Vildagliptin showed anti-epileptic effects and promoted subthreshold A-type potassium currents by regulating DPPs and Kv4s binding
Godad et al. Animal Models of CNS Neurodegenerative Disease/Research Implications of Animal Models of CNS Neurodegenerative Diseases
Cavalcante et al. GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders
Wheeler Functional recovery following spinal cord injury: remyelination as a therapeutic target in aging
CA2968933C (en) Peptides for use in neurodegenerative disorders
Mohajerani Low acetylcholine during early sleep is crucial for motor memory consolidation
Altimimi Mechanisms and in vivo functions for Tumor Necrosis Factor alpha-dependent non-Hebbian synaptic plasticity
Vijayaraghavan et al. frontiers MINI REVIEW in Synaptic Neuroscience published: 19 June 2015 doi: 10.3389/fnsyn. 2015.00010
Nedelcovych Selective Antagonism of mGluR5 Alters Sleep-Wake and Quantitative EEG and Ameliorates Behavioral Abnormalities in a Rodent Model of Traumatic Stress

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200417

Application number text: 1020197008907

Filing date: 20190327

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200515

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200520

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210118

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200520

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210419

Application number text: 1020197008907

Filing date: 20190327